Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mink Therapeutics Inc (NQ: INKT ) 0.9055 +0.0055 (+0.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 69,653 Open 0.9100 Bid (Size) 0.8800 (1) Ask (Size) 0.9600 (1) Prev. Close 0.9000 Today's Range 0.8800 - 0.9640 52wk Range 0.7500 - 1.960 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MiNK Therapeutics Announces Virtual Annual Shareholders Meeting June 05, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting May 22, 2024 From MiNK Therapeutics Via GlobeNewswire Performance YTD -16.93% -16.93% 1 Month +0.61% +0.61% 3 Month +1.29% +1.29% 6 Month +1.54% +1.54% 1 Year -48.55% -48.55% More News Read More INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 May 14, 2024 Via InvestorPlace MiNK Reports First Quarter 2024 Results May 14, 2024 From MiNK Therapeutics Via GlobeNewswire Earnings Outlook For MiNK Therapeutics March 20, 2024 Via Benzinga Why MiNK Therapeutics Stock Is Up 11% Monday May 13, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session May 13, 2024 Via Benzinga MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer May 13, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK to Provide Corporate Update and First Quarter 2024 Financial Report April 30, 2024 From MiNK Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session April 08, 2024 Via Benzinga MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR April 08, 2024 From MiNK Therapeutics Via GlobeNewswire Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session April 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session April 05, 2024 Via Benzinga INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 March 21, 2024 Via InvestorPlace MiNK Reports Fourth Quarter and Year-End 2023 Results March 21, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report March 07, 2024 From MiNK Therapeutics Via GlobeNewswire Earnings Scheduled For March 21, 2024 March 21, 2024 Via Benzinga MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 March 06, 2024 From MiNK Therapeutics Via GlobeNewswire First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab February 14, 2024 From MiNK Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session February 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications February 06, 2024 From MiNK Therapeutics Via GlobeNewswire MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene January 30, 2024 From MiNK Therapeutics Via GlobeNewswire ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development December 20, 2023 From MiNK Therapeutics Via GlobeNewswire MiNK Therapeutics Reports Third Quarter 2023 Results November 09, 2023 From MiNK Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
